Rubius Therapeutics EPS Ratio 2011-2026 | RUBY

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Rubius Therapeutics

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-1.99	-2.23	-2.08	-2.08	-2.27	-5.55	-1.63	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-1.63	-5.55	-2.55

Quarterly EPS Ratio Rubius Therapeutics

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-0.7	-0.49	-0.58	-	-0.55	-0.56	-0.51	-0.5	-0.51	-0.47	-0.6	-0.56	-0.59	-0.5	-0.42	-0.35	-0.42	-2.43	-1.72	-2.07	-1.48	-1.25	-0.68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-0.35	-2.43	-0.815

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Verastem VSTM	-3.02	$ 5.04	-4.73 %	$ 349 M	USA
Voyager Therapeutics VYGR	-2.04	$ 3.96	-4.12 %	$ 232 M	USA
VistaGen Therapeutics VTGN	-1.67	$ 0.57	-5.87 %	$ 17.6 M	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-2.38	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	-1.77	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	-1.96	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Arena Pharmaceuticals ARNA	-10.1	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	-15.8	-	-52.27 %	$ 4.45 M	USA
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Atreca BCEL	-2.52	-	-11.76 %	$ 5.79 M	USA
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	-1.93	-	-	$ 546 M	USA
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Avid Bioservices CDMO	-2.23	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Adaptive Biotechnologies Corporation ADPT	-0.39	$ 12.41	-11.1 %	$ 1.88 B	USA
Wave Life Sciences Ltd. WVE	-1.21	$ 6.37	2.66 %	$ 1.07 B	Singapore
Xenetic Biosciences XBIO	-1.58	$ 2.72	-2.86 %	$ 4.63 M	USA
XBiotech XBIT	-1.49	$ 2.27	-1.73 %	$ 69.2 M	USA
Xenon Pharmaceuticals XENE	-3.01	$ 54.48	-1.89 %	$ 4.24 B	Canada
Xeris Pharmaceuticals XERS	-0.37	$ 5.4	-3.05 %	$ 866 M	USA
X4 Pharmaceuticals XFOR	-1.87	$ 4.04	-6.26 %	$ 171 M	USA
Xencor XNCR	-1.24	$ 11.42	-7.23 %	$ 848 M	USA
XOMA Corporation XOMA	1.53	$ 30.17	-1.18 %	$ 364 M	USA
BeiGene, Ltd. BGNE	0.2	-	0.49 %	$ 251 B	Cayman-islands
22nd Century Group XXII	-52.9	$ 2.41	-18.03 %	$ 444 K	USA
BioDelivery Sciences International BDSI	0.85	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	-2.19	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	-1.89	-	-	$ 3.74 B	USA
Zai Lab Limited ZLAB	-0.16	$ 18.0	2.8 %	$ 19.7 B	China
Enlivex Therapeutics Ltd. ENLV	-0.73	$ 1.05	-3.67 %	$ 21.5 M	Israel
Enochian Biosciences ENOB	-1.08	-	-	$ 40.5 M	USA